S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:TARA

Protara Therapeutics Stock Forecast, Price & News

$14.27
+0.52 (+3.78 %)
(As of 03/5/2021 04:30 PM ET)
Add
Compare
Today's Range
$13.15
Now: $14.27
$14.62
50-Day Range
$16.05
MA: $19.43
$22.44
52-Week Range
$12.51
Now: $14.27
$67.08
Volume107,795 shs
Average Volume94,074 shs
Market Capitalization$160.00 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17
Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.
Protara Therapeutics logo

Headlines

Is TARA A Good Stock To Buy Now?
December 17, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TARA
CUSIPN/A
CIKN/A
Phone646-844-0337
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($21.67) per share

Profitability

Net Income$-14,990,000.00

Miscellaneous

Market Cap$160.00 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.85 out of 5 stars

Medical Sector

134th out of 1,972 stocks

Biological Products, Except Diagnostic Industry

14th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
$14.27
+0.52 (+3.78 %)
(As of 03/5/2021 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TARA News and Ratings via Email

Sign-up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Protara Therapeutics (NASDAQ:TARA) Frequently Asked Questions

Is Protara Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Protara Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Protara Therapeutics stock.
View analyst ratings for Protara Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Protara Therapeutics?

Wall Street analysts have given Protara Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Protara Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Protara Therapeutics?

Protara Therapeutics saw a increase in short interest in the month of January. As of January 29th, there was short interest totaling 135,500 shares, an increase of 25.1% from the January 14th total of 108,300 shares. Based on an average daily trading volume, of 93,600 shares, the days-to-cover ratio is currently 1.4 days. Approximately 1.4% of the company's stock are sold short.
View Protara Therapeutics' Short Interest
.

When is Protara Therapeutics' next earnings date?

Protara Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Protara Therapeutics
.

How were Protara Therapeutics' earnings last quarter?

Protara Therapeutics, Inc. (NASDAQ:TARA) announced its earnings results on Thursday, November, 12th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.76.
View Protara Therapeutics' earnings history
.

How has Protara Therapeutics' stock been impacted by Coronavirus?

Protara Therapeutics' stock was trading at $24.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TARA stock has decreased by 40.6% and is now trading at $14.27.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for TARA?

3 Wall Street analysts have issued 1-year price targets for Protara Therapeutics' stock. Their forecasts range from $43.00 to $50.00. On average, they expect Protara Therapeutics' stock price to reach $47.67 in the next year. This suggests a possible upside of 234.0% from the stock's current price.
View analysts' price targets for Protara Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Protara Therapeutics' key executives?

Protara Therapeutics' management team includes the following people:
  • Mr. Jesse Shefferman, Co-Founder, CEO, Pres & Director (Age 49, Pay $379.08k)
  • Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D., Chief Scientific Operations Officer (Age 40, Pay $306.59k)
  • Mr. Blaine T. Davis, CFO and Principal Financial & Accounting Officer (Age 47)
  • Ashley Garry, Sec.

Who are some of Protara Therapeutics' key competitors?

What other stocks do shareholders of Protara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protara Therapeutics investors own include Immunic (IMUX), Trevena (TRVN), AIM ImmunoTech (AIM), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), CorMedix (CRMD), CTI BioPharma (CTIC), Fortress Biotech (FBIO), Genocea Biosciences (GNCA) and Otonomy (OTIC).

What is Protara Therapeutics' stock symbol?

Protara Therapeutics trades on the NASDAQ under the ticker symbol "TARA."

Who are Protara Therapeutics' major shareholders?

Protara Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Ikarian Capital LLC (5.79%), Price T Rowe Associates Inc. MD (3.87%), Artisan Partners Limited Partnership (3.36%), BlackRock Inc. (1.62%), Alyeska Investment Group L.P. (0.66%) and Alyeska Investment Group L.P. (0.66%). Company insiders that own Protara Therapeutics stock include Blaine Davis, Opaleye Management Inc and Randall Marshall.
View institutional ownership trends for Protara Therapeutics
.

Which institutional investors are selling Protara Therapeutics stock?

TARA stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Alyeska Investment Group L.P., Ikarian Capital LLC, Renaissance Technologies LLC, Price T Rowe Associates Inc. MD, and Wells Fargo & Company MN.
View insider buying and selling activity for Protara Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Protara Therapeutics stock?

TARA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Artisan Partners Limited Partnership, Tri Locum Partners LP, Northern Trust Corp, Bank of New York Mellon Corp, Nuveen Asset Management LLC, Charles Schwab Investment Management Inc., and American International Group Inc.. Company insiders that have bought Protara Therapeutics stock in the last two years include Blaine Davis, and Opaleye Management Inc.
View insider buying and selling activity for Protara Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Protara Therapeutics?

Shares of TARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protara Therapeutics' stock price today?

One share of TARA stock can currently be purchased for approximately $14.27.

How much money does Protara Therapeutics make?

Protara Therapeutics has a market capitalization of $160.00 million.

What is Protara Therapeutics' official website?

The official website for Protara Therapeutics is www.proteontherapeutics.com.

Where are Protara Therapeutics' headquarters?

Protara Therapeutics is headquartered at 1 LITTLE WEST 12TH STREET, NEW YORK NY, 10014.

How can I contact Protara Therapeutics?

Protara Therapeutics' mailing address is 1 LITTLE WEST 12TH STREET, NEW YORK NY, 10014. The company can be reached via phone at 646-844-0337 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.